Health Care Cost

Latest News

3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
Individualized Niraparib Starter Dosing Cuts AE Costs in Ovarian Cancer by 48%

December 9th 2024

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD) in US patients with ovarian cancer.

AJMC
Out-of-Pocket Spending for Cardiac Rehabilitation and Adherence Among US Adults

December 9th 2024

Center on Health Equity and Access
Health Equity & Access Weekly Roundup: December 7, 2024

December 7th 2024

AJMC
The Health Care Price Crisis Needs Policy Solutions

December 6th 2024

Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg
Prior Authorization Delays Cause Serious Harm to Patients With Cancer

December 4th 2024

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo